HC Wainwright Has Bullish Estimate for ESPR FY2025 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Investment analysts at HC Wainwright lifted their FY2025 earnings per share estimates for Esperion Therapeutics in a research note issued to investors on Tuesday, January 13th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will earn ($0.15) per share for the year, up from their previous forecast of ($0.42). HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Esperion Therapeutics’ Q4 2025 earnings at $0.02 EPS, FY2026 earnings at $0.58 EPS and FY2027 earnings at $0.81 EPS.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.07). The firm had revenue of $87.31 million for the quarter, compared to analysts’ expectations of $78.33 million.

A number of other equities research analysts have also weighed in on the company. Wall Street Zen raised Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, January 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Esperion Therapeutics in a report on Wednesday, October 8th. Citigroup reissued a “market outperform” rating on shares of Esperion Therapeutics in a research report on Wednesday, November 12th. Piper Sandler began coverage on shares of Esperion Therapeutics in a research note on Tuesday, November 25th. They set an “overweight” rating and a $9.00 price objective for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Esperion Therapeutics in a report on Wednesday, November 12th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $7.20.

Esperion Therapeutics Stock Down 2.9%

Esperion Therapeutics stock opened at $3.04 on Thursday. The firm has a fifty day simple moving average of $3.58 and a two-hundred day simple moving average of $2.67. Esperion Therapeutics has a twelve month low of $0.69 and a twelve month high of $4.18. The company has a market capitalization of $726.74 million, a PE ratio of -6.08, a P/E/G ratio of 6.39 and a beta of 1.04.

Insider Activity

In related news, CFO Benjamin Halladay sold 7,337 shares of the business’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $3.67, for a total transaction of $26,926.79. Following the transaction, the chief financial officer owned 467,525 shares in the company, valued at $1,715,816.75. The trade was a 1.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Two Seas Capital LP increased its stake in shares of Esperion Therapeutics by 43.6% in the 2nd quarter. Two Seas Capital LP now owns 9,954,975 shares of the biopharmaceutical company’s stock worth $9,800,000 after acquiring an additional 3,024,104 shares in the last quarter. Parallel Advisors LLC grew its holdings in Esperion Therapeutics by 1,174.2% in the second quarter. Parallel Advisors LLC now owns 127,424 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 117,424 shares during the period. UMB Bank n.a. purchased a new stake in Esperion Therapeutics in the second quarter worth about $167,000. Summit Wealth Group LLC increased its stake in shares of Esperion Therapeutics by 10.2% during the second quarter. Summit Wealth Group LLC now owns 323,000 shares of the biopharmaceutical company’s stock valued at $318,000 after purchasing an additional 30,000 shares in the last quarter. Finally, Diametric Capital LP lifted its holdings in shares of Esperion Therapeutics by 57.8% during the second quarter. Diametric Capital LP now owns 678,824 shares of the biopharmaceutical company’s stock valued at $668,000 after purchasing an additional 248,648 shares during the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.